Bioretec Oy Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Timo Lehtonen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	5.3yrs
CEO ownership	n/a
Management average tenure	3.2yrs
Board average tenure	1.5yrs

Recent management updates

Recent updates

CEO

Timo Lehtonen (48 yo)

5.3yrs

Tenure

Timo Lehtonen has been the Chief Executive Officer of Bioretec Oy since 2019. Timo Lehtonen serves as a member of the Board of Directors of Naturans Oy. Timo Lehtonen holds a Master of Science degree in Te...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Timo Lehtonen	Chief Executive Officer	5.3yrs	no data	no data
Johanna Salko	Chief Financial Officer	3.2yrs	no data	no data
Esa Hallinen	Director of Operations	less than a year	no data	no data
Kimmo Lahteenkorva	Chief Technology Officer	7.3yrs	no data	no data
Rami Ojala	Sales & Marketing Director	2.3yrs	no data	no data

3.2yrs

Average Tenure

56yo

Average Age

Experienced Management: 0TN's management team is considered experienced (3.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Tomi Numminen	Chairman of the Board	7.9yrs	no data	no data
Pekka Simula	Director	4.3yrs	no data	no data
Kustaa Poutiainen	Director	less than a year	no data	no data
Sarah Van Hellenberg Hubar-Fisher	Director	3yrs	no data	no data
Michael Piccirillo	Director	6.3yrs	no data	no data
Paivi Malinen	Director	2yrs	no data	no data
Klaus Dresing	Member of Scientific Advisory Board	no data	no data	no data
Fan Liu	Member of Scientific Advisory Board	1.1yrs	no data	no data
Theddy Slongo	Member of Scientific Advisory Board	no data	no data	no data
Jeffrey Wang	Member of Scientific Advisory Board	1.1yrs	no data	no data
Richard Assaker	Member of Scientific Advisory Board	1.1yrs	no data	no data
Stefan Rammelt	Member of Scientific Advisory Board	less than a year	no data	no data

1.5yrs

Average Tenure

50.5yo

Average Age

Experienced Board: 0TN's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Bioretec Oy Management

Management criteria checks 1/4

Key information

Recent management updates

Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors

Bioretec Ltd Announces CEO Changes

Bioretec Ltd Unveils Its Revitalized Scientific Advisory Board

Bioretec Oy Appoints Esa Hallinen as Director of Operations and Member of the Management Team

Bioretec Oy Approves Management Appointments

Bioretec Ltd Appoints Dr. Jeremy Dublon as Regulatory Advisor

Recent updates

Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors

Bioretec Ltd. Receives a Patent by the U.S. Patent Office for its RemeOs Magnesium Alloy Composition

Bioretec Has Been Granted FDA Breakthrough Device Designation Status for its RemeOs Spinal Interbody Cage

Bioretec's European Market Authorization for RemeOs Trauma Screw Proceeded to Expert Panel Evaluation

Bioretec Oy to Report Q2, 2024 Results on Aug 15, 2024

Bioretec Ltd Announces CEO Changes

New minor risk - Share price stability

Bioretec Estimates the Approval of the European Market Authorization for the Biodegradable RemeOs™ Trauma Screw Will Move to the First Quarter of 2024

Bioretec Estimates the Approval of the European Market Authorization for the Biodegradable RemeOs™ Trauma Screw Will Move to the First Quarter of 2024

Bioretec Ltd Unveils Its Revitalized Scientific Advisory Board

Bioretec Oy Appoints Esa Hallinen as Director of Operations and Member of the Management Team

Bioretec Oy Approves Management Appointments

Bioretec Ltd Appoints Dr. Jeremy Dublon as Regulatory Advisor

No independent directors

Bioretec Ltd Submits Additional Information Requested by the FDA for US Registration of RemeOs Trauma Screws

Bioretec Oy to Report First Half, 2023 Results on Aug 11, 2023

No independent directors

Bioretec Ltd, Updates Estimate of U.S. registration of RemeOs™ Screws and Expects Approval in April 2023

Bioretec's Hybrid Composite Patent Has Been Approved in Europe

Bioretec Oy Announces ActivaPin Bioresorbable Implant Provides Good Alternative Treatment of Pediatric Elbow Injuries

Bioretec Ltd Announces Bioresorbable Activa IM-Nail™ Shows Convincing Results in Post-Market Clinical Follow Up Study for the Treatment of Children's Forearm Fractures

Bioretec Ltd Submits Market Authorization Request for Its Bioresorbable RemeOs™ Magnesium Screw in the U.S

No independent directors

Bioretec's ActivaPin(TM) Bioresorbable Implant Provides Excellent Clinical Outcome in the Treatment of Pediatric Wrist Fractures

Bioretec Oy Announces Appointment of Päivi Malinen as Member of the Board of Directors

No independent directors

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age